Please login to the form below

Not currently logged in
Email:
Password:

Johan Heylen leaves GSK for Ablynx

He joins Nanobody specialist as chief commercial officer

edit-Johan-Heylen_Chief-Commercial-Officer_AblynxAblynx has named former GlaxoSmithKline (GSK) executive Johan Heylen as chief commercial officer.

Heylen spent 17 years at GSK, serving most recently as executive director, global commercial lead for its cancer immunotherapeutics division.

In this role he headed the global commercial teams of GSK and was responsible for the development and implementation of the launch strategy for several drugs, including Rotarix, Priorix and Varilix.

Heylen now heads commercial operations at Ablynx, growing biopharma specialising in the development of Nanobodies, tiny fragments of antibodies with therapeutic potential.

He said: "Ablynx has an extraordinary pipeline of products based on its unique Nanobody discovery platform, validated by an impressive list of partners.

“I look forward to working with the first-class team to support the company as it moves to the next stage of development and begins to anticipate the commercialisation of the first Nanobody-based therapeutics."

Heylen also has experience at Servier and Wyeth having started his career in healthcare as a pharmacist.

20th November 2014

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....